|
Emetogenisity
|
Actual measure (Early)
|
Actual measure (Delayed)
|
n
|
Compliance
|
|---|
|
Minimal
|
5-HT3RA + DEX
|
no
|
2
|
Sufficient
|
|
5-HT3RA
|
no
|
1
|
Sufficient
|
|
DEX
|
no
|
1
|
Sufficient
|
|
no
|
no
|
3
|
Sufficient
|
|
Low
|
5-HT3RA + DEX
|
no
|
29
|
Sufficient
|
|
5-HT3RA + DEX
|
DEX
|
3
|
Sufficient
|
|
5-HT3RA + DEX
|
D2RA
|
1
|
Sufficient
|
|
DEX
|
DEX
|
1
|
Sufficient
|
|
DEX
|
no
|
3
|
Sufficient
|
|
no
|
no
|
1
|
Insufficient
|
|
Moderate
|
5-HT3RA + DEX
|
DEX
|
6
|
Sufficient
|
|
5-HT3RA + DEX
|
NK1RA + DEX
|
3
|
Sufficient
|
|
NK1RA + 5-HT3RA + DEX
|
NK1RA
|
2
|
Sufficient
|
|
NK1RA + 5-HT3RA + steroid (MM)
|
NK1RA
|
1
|
Sufficient
|
|
NK1RA + 5-HT3RA + DEX
|
5-HT3RA + DEX + NK1RA
|
1
|
Sufficient
|
|
5-HT3RA + DEX
|
no
|
3
|
Insufficient
|
|
5-HT3RA + DEX
|
DEX + D2RA
|
1
|
Sufficient
|
|
High
|
NK1RA + 5-HT3RA + DEX
|
NK1RA
|
2
|
Insufficient
|
|
NK1RA + 5-HT3RA + steroid (ML)
|
NK1RA
|
2
|
Sufficient
|
|
NK1RA + 5-HT3RA + steroid (ML)
|
NK1RA + D2RA
|
1
|
Sufficient
|
|
5-HT3RA + DEX
|
DEX
|
2
|
Insufficient
|
|
5-HT3RA + DEX
|
no
|
1
|
Insufficient
|
- 5-HT3RA; 5-HT3 receptor antagonist, DEX; Dexamethasone, D2RA; Dopamine receptor D2 receptor antagonist, NK1RA; Neurokinin 1 receptor antagonist, MM; multiple myeloma, ML; malignant lymphoma.
